Array BioPharma IncFind Ratings Reports
ARRAY BIOPHARMA INC's gross profit margin for the fourth quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not.
At the same time, stockholders' equity ("net worth") has greatly increased by 130.91% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||33.78||43.21|
|Net Income ($mil)||-29.59||-25.01|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||235.06||109.94|
|Total Assets ($mil)||279.15||168.9|
|Total Debt ($mil)||121.31||113.66|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||70.12||87.98|
|Return on Assets||-41.84||-54.96|
|Return on Equity||-996.14||0.0|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||169.9||143.69|
|Div / share||0.0||0.0|
|Book value / share||0.07||-0.26|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2774501.0||4127933.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 127.25 indicates a significant premium versus the S&P 500 average of 3.02 and a significant premium versus the industry average of 10.65. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ARRAY BIOPHARMA INC proves to trade at a premium to investment alternatives within the industry.
|ARRY NM||Peers 37.70||ARRY NA||Peers 25.05|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ARRY's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|ARRY NM||Peers 24.88||ARRY NA||Peers 0.44|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ARRY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ARRY 127.25||Peers 10.65||ARRY -10.76||Peers 12.57|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ARRY is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ARRY is expected to significantly trail its peers on the basis of its earnings growth rate.
|ARRY 9.89||Peers 143.41||ARRY 9.40||Peers 358.36|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ARRY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ARRY significantly trails its peers on the basis of sales growth